| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 570,450 | 402,360 | 276,570 | 246,580 | 226,690 |
| Sales Growth | +41.78% | +45.48% | +12.16% | +8.77% | +9.17% |
| Net Income | -70,170 | -2,300 | -3,280 | 12,680 | -3,780 |
| Net Income Growth | -2,950.87% | +29.88% | -125.87% | +435.45% | +88.30% |
Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.
Fiscal Year End Date: 12/31